AI assistant
Humacyte, Inc. — Director's Dealing 2024
May 16, 2024
33410_dirs_2024-05-15_d0791793-1dea-4e86-8a38-d166ce672f86.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2024-05-15
Reporting Person: Binder Gordon M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-15 | Common Stock | P | 50000 | $6.57 | Acquired | 50000 | Indirect |
| 2024-05-15 | Common Stock | P | 50000 | $6.78 | Acquired | 160000 | Direct |
Footnotes
F1: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.